HPV PepMix Pools: Antigen-Spanning Peptides for HPV Strains

HPV

About Human papillomavirus

JPT's HPV Peptide Tools

Filter products

Cancer biomarker research

T-cell immunity

PepMix Collections

PepMix Peptide Pools

PepMix Peptide Pools Infections

Cancer

Genital malignancies

Infection

Malignant genital cancers

Papillomas

Human Papillomavirus (HPV)

Major capsid protein

Minor capsid protein

Probable protein E5

Protein E1

Protein E4

Protein E6

Protein E7

Protein L1

Protein L2

Regulatory protein

Replication protein

Selected proteins

No

PepMix™ Collection HPV (E6)

US$3,432.00

PepMix™ Collection HPV (E7)

PepMix™ Collection Papillomavirus

US$3,426.80

PepMix™ HPV 06 (E6)

US$572.00

PepMix™ HPV 06 (E7)

US$599.30

PepMix™ HPV 11 (E6)

PepMix™ HPV 11 (E7)

PepMix™ HPV 16 (E6)

PepMix™ HPV 16 (E7)

PepMix™ HPV 16 (L2)

US$698.10

Cellular Immune Response

Antigen specific stimulation of T-cells

Immune monitoring of high-risk patients

Qualification of immunodominant antigens

Validating clinical T-cell assays

We offer 21 different antigen-spanning HPV PepMixes from e.g. HPV06, HPV11, HPV16, HPV18, HPV35, HPV45 and HPV58 covering proteins such as E1, E2, E4, E5, E6, E7 and L1.

Custom PepMix™ Peptide Pools for your specific needs

T-cell assays in

High-throughput T-cell epitope discovery

Monitoring of cellular immune response

Clinical trials

Humoral Immune Response

Immune monitoring of humoral responses

Profiling of HIV specific samples or antibodies

Evaluation of co-infection

Detection of epitopes and epitope spreading

Clinical Peptides

References

Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumorsSethi et al., NPJ Vaccines (2025)Products used: PepMix™ VZV (gE), PepMix™ HPV 18 (L1) or PepMix™ HPV16 (L1)

High Treg and PMN-MDSC densities are a hallmark of tertiary lymphoid structures in fatal cases of cervical cancerSyding et al., Journal of Immunotherapy for Cancer (2025) Products used: PepMix™ HPV 16 (E6), PepMix™ HPV 16 (E7)

Role of prior HPV infection and CD4 T‑cell count in modulating cellular immune responses to a three‑dose nonavalent HPV vaccine schedule in PWH receiving ARTTortellini et al., BMC Medicine (2025) - PMID: 41444940Products used: PepMix™ HPV16 (L1), PepMix™ HPV 18 (L1)

Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer CellsJacques et al., Cancers (2024)Product used: PepMix HPV16 (L1)

Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model Sanders et al., Vaccines (2023) - PMID: 37270364

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies Minnar et al., Journal of Immunology (2022) - PMID: 35764364 Product used: PepMix HPV 16 (E7)

Incorporation of RG1 Epitope Into HPV16L1-VLP Does Not Compromise L1-Specific ImmunitySchellenbacher et al, Vaccine (2019)

Characterization of Recombinant Gorilla Adenovirus HPV Therapeutic Vaccine PRGN-2009Samuel T. Pellom et al., JCI Insight, (2021)

First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced CancersFenne L. Komdeur et al., Mol Therapy, (2021)

Human Papilloma Virus-Specific T Cells can be Generated from Naïve T Cells for use as an Immunotherapeutic Strategy for Immunocompromised PatientsMcCormack et al., Cytotherapy (2018)

Development of a Replication-Deficient Adenoviral Vector-Based Vaccine Candidate for the Interception of HPV16- and HPV18-Induced Infections and DiseaseRamos et al., International Jounal of Cancer (2017)

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Huber et al., PLoS One (2017)

Testimonial